Species-specific responses to MHC molecules in SIV vaccination and infection.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Species-specific responses to MHC molecules in SIV vaccination and infection.

Symp Nonhum Primate Models AIDS. 1993 Sep 19-22;11:abstract no. 27. Unique Identifier : AIDSLINE PRIM11/94191620
Cranage M; Polyanskaya N; Cook N; Webster S; Dennis M; Sharpe S; Ashworth T; Hall G; Centre for Applied Microbiology and Research, Porton Down,; Salisbury, U.K.

Abstract: It is known that some retroviruses, including HIV and SIV selectively incorporate host cell proteins into their envelopes during virus egress from the infected cell. Recent results have shown that vaccine mediated protection in macaques, seen when vaccine and challenge virus are prepared in human cells, is, at least in part, due to antibody responses directed against these host cell proteins. We have reported previously that protected macaques vaccinated with SIV grown on C8166 cells make a major antibody response to human MHC class-I antigens. No absolute correlation between such responses and protection has been seen. We now show that vaccinates also make antibody responses against HLA class-II DR antigens. These anti human responses are unique to animals vaccinated with virus grown on human cells and do not appear in infected animals. In contrast, we report that infected animals make antibody responses directed against rhesus MHC antigens. These data suggest either that SIV antigens may mimic regions of rhesus MHC molecules, in a species-specific manner, or that infected animals recognise altered or non-self MHC antigens. To determine if allo-cell responses can protect macaques against challenge with SIV grown on monkey PBMC, we have prepared and titrated an SIV cell-free challenge pool on PBMCs taken from a limited number of macaques. Four macaques were then vaccinated with paraformaldehyde-fixed monkey PBMC taken from the same animals as used to produce the virus challenge stock. Data on the immune responses and on the outcome of challenge will be presented.

Keywords: Animal Antibody Formation Cell Line Histocompatibility Antigens/*IMMUNOLOGY Histocompatibility Antigens Class I/IMMUNOLOGY Human HLA-DR Antigens/IMMUNOLOGY Lymphocytes/IMMUNOLOGY/MICROBIOLOGY Macaca Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/*PREVENTION & CONTROL Species Specificity SIV/GROWTH & DEVELOPMENT/*IMMUNOLOGY Viral Vaccines/*IMMUNOLOGY ABSTRACT
940730
M9470898

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .